Five-Year Follow up of Prostate Adenocarcinoma Patients Treated with Interstitial High Dose Rate Brachytherapy Monotherapy, A Single-center Experience

Five-Year Follow up of Prostate Adenocarcinoma Patients Treated with Interstitial High Dose Rate Brachytherapy Monotherapy, A Single-center Experience
PropertyValue
Title:Five-Year Follow up of Prostate Adenocarcinoma Patients Treated with Interstitial High Dose Rate Brachytherapy Monotherapy, A Single-center Experience
Author/Abstract:

Kim Anthony Soronio, MD; Caissa Elvira Tangco, MD; Marcelino L. Morales Jr., MD, FPUA;
Juan Martin Magsanoc, MD; Frances Lily Lantin-Penano, MD and Patrick Vincent Tanseco, MD
Institute of Urology, St Luke's Medical Center

Objective: Prostate cancer is the most common cancer in men and localized prostate adenocarcinoma
has multiple treatment options. In this study, the objective was to review the outcome of patients that
were treated with HDR brachytherapy as monotherapy in all prostate adenocarcinoma patients at the
St Luke's Medical Center.

Materials and Methods: Thirty three (33) patients who underwent HDR prostate brachytherapy as
monotherapy for prostate adenocarcinoma in a single institution for the past 5 years received 38 Gy
in 4 fractions. The charts of these patients were reviewed to determine biochemical control using the
Phoenix criteria and ASTRO definition, and toxicity.

Results: Patients showed good biochemical control, with 92.16% meeting the target PSA value of 2
ng/mL or less and a 96.51% without consecutive rise of PSA post brachytherapy. There was also
minimal toxicity, with no report of gastrointestinal toxicity and 9.1% rate of temporary genitourinary
toxicity.

Conclusion: Good biochemical control of prostate adenocarcinoma was achieved with the use of
HDR brachytherapy as monotherapy, with a minimal toxicity profile.

Key words: Prostate adenocarcinoma, brachytherapy

Filesize: 333.48 kB
Filetype:pdf (Mime Type: application/pdf)